Ascletis Pharma Inc.

Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-β Agonist ASC41
2021-02-21
Ascletis Joins Sagimet’s US$80 Million in Crossover Financing with Premium Investors
2021-02-11
Gannex Announces Positive Phase I Clinical Results on Its THR-β Agonist ASC41
2021-01-12

3

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备 11050387号